Farmaseuttinen koostumus ja menetelmä sen valmistamiseksi

PCT No. PCT/HU92/00060 Sec. 371 Date Jun. 17, 1994 Sec. 102(e) Date Jun. 17, 1994 PCT Filed Dec. 18, 1992 PCT Pub. No. WO93/12775 PCT Pub. Date Jul. 8, 1993The invention relates to two phase pharmaceutical compositions comprising as active ingredient a MAO inhibitor and an uptake inhibitor together...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	GAAOL, JOZSEF, LENGYEL, JOZSEF, MARMAROSI, KATALIN, SZIRAKI, ISTVAN, SZATMARI, ISTVAN, Z.SZABO, ANNA, HERMECZ, ISTVAN, KOERMOECZY, PETER, MAGYAR, KALMAN, TOEROEK, ZOLTAN
Format:	Patent
Sprache:	fin ; swe
Schlagworte:	ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PCT No. PCT/HU92/00060 Sec. 371 Date Jun. 17, 1994 Sec. 102(e) Date Jun. 17, 1994 PCT Filed Dec. 18, 1992 PCT Pub. No. WO93/12775 PCT Pub. Date Jul. 8, 1993The invention relates to two phase pharmaceutical compositions comprising as active ingredient a MAO inhibitor and an uptake inhibitor together with usual pharmaceutical auxiliaries. The compositions can be used for the treatment of neurodegenerative diseases. As active ingredient optionally N-(1-phenyl-isopropyl)-N-methyl-propinylamine or N-(4-fluoro-phenyl)-isoprop-1-yl-N-methyl-propinylamine or their salts, optically active isomers or metabolites are used both as MAO inhibitor and as uptake inhibitor.